Loading data for LLY — first visit, this takes a few seconds.

Eli Lilly and Company (LLY)

NYSE: LLY · 即時價格 · USD

1,123.00

-1.21 (-0.11%)

收盤價： Sep 11, 2026, 10:38 AM

1,116.29

+0.05%

盤後: 6:15 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

-0.11% (1D)

買價	1123.92
市值	995B
營收 (ttm)	79.7B
淨利（ttm）	26.7B
	0.50
	29.76
	37.49
	23.62
P/B (ttm)	29.36
P/S (ttm)	12.48
財報日期	Oct 29, 2026

賣價	1131
成交量	1,991,604
20 日平均成交量	2,773,381
開盤價	1126.08
前收盤價	1124.21
當日區間	1121.07 - 1133.79
52 週範圍	712.05 - 1292.65
分析師	n/a
目標價	n/a
股利	$6.92 (0.62%)
除息日	Aug 14, 2026

關於 LLY

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabe...

[閱讀更多]

產業 Drug Manufacturers - General

類股 Healthcare

IPO 日期 Jun 1, 1972

員工 50,000

證券交易所 NYSE

股票代號 LLY

網站 https://www.lilly.com

完整的公司簡介

財務表現

Eli Lilly and Company 在 2025 年的營收為 65.18B，較前一年的 45.04B 增加 44.7%。淨利為 20.64B，較前期增加 94.9%。

財務報表

財報驚奇

Eli Lilly and Company 已於 Aug 5, 2026 公布季度財報：

營收為 $22.97B 低於預期 $0, 年增 47.67% 成長.
每股盈餘為 8.38 超出預期 1.80, 年增 32.81% 成長.

下次財報發布

Eli Lilly and Company 的下次財報預計於 Oct 29, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

23 小時前 · Trefis

Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?

In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.

1 日前 · Trefis

JNJ Stock: Is the Rally Running Out of Steam?

A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.

1 日前 · 24/7 Wall St.

Got $10,000? Eli Lilly vs. Nvidia: The Better Buy For 2026

Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds the sharper edge he...

1 日前 · 24/7 Wall St.

Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?

Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this p...

1 日前 · Zacks

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.

第 1 頁，共 2 頁

Eli Lilly and Company (LLY)